Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting

Pfohl, Martin; Jornayvaz, François; Fritsche, Andreas; Pscherer, Stefan; Anderten, Helmut; Pegelow, Katrin; Seufert, Jochen

doi:10.1111/dom.13952

Scientific article

Open access

English

Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting

ContributorsPfohl, Martin; Jornayvaz, François; Fritsche, Andreas; Pscherer, Stefan; Anderten, Helmut; Pegelow, Katrin; Seufert, Jochen

Published inDiabetes, Obesity and Metabolism, vol. 22, no. 5, p. 759-766

Publication date2020

Abstract

To evaluate the effectiveness and safety of initiating basal insulin-supported oral therapy (BOT) with insulin glargine 300 U/mL (Gla-300) in patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs (OADs).

Keywords

Glycaemic control
Hypoglycaemia
Insulin analogues
Observational study
Type 2 diabetes

Affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Research group

Laboratoire de recherche NAFLD et résistance à l'insuline (997)

Citation (ISO format)

PFOHL, Martin et al. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting. In: Diabetes, Obesity and Metabolism, 2020, vol. 22, n° 5, p. 759–766. doi: 10.1111/dom.13952

Article (Published version)

CC BY-NC

Identifiers

PID : unige:138892
DOI : 10.1111/dom.13952
PMID : 31903680

Commercial URLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187365/

ISSN of the journal1462-8902

417views

293downloads

Creation08/04/2020 10:41:00 AM

First validation08/04/2020 10:41:00 AM

Update time03/15/2023 10:22:49 PM

Status update03/15/2023 10:22:48 PM

Last indexation02/12/2024 1:16:53 PM

Archive ouverte UNIGE

Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting

To evaluate the effectiveness and safety of initiating basal insulin-supported oral therapy (BOT) with insulin glargine 300 U/mL (Gla-300) in patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs (OADs).

Technical informations